

Mechanisms of organophosphate insecticide-induced airway hyperreactivity

Allison D. Fryer, Pamela J. Lein, Angela S. Howard,
Bethany L. Yost, Rondell A. Beckles, and David A. Jett

Department of Environmental Health Sciences, Johns Hopkins University
Bloomberg School of Public Health, Baltimore, Maryland 21205

Submitted 25 September 2003; accepted in final form 23 December 2003

Fryer, Allison D., Pamela J. Lein, Angela S. Howard, Bethany L. Yost, Rondell A. Beckles, and David A. Jett. Mechanisms of organophosphate insecticide-induced airway hyperreactivity. *Am J Physiol Lung Cell Mol Physiol* 286: L963–L969, 2004. First published January 2, 2004; 10.1152/ajplung.00343.2003.—It has been suggested that pesticide exposure may be a contributing factor underlying the increased incidence of asthma in the United States and other industrialized nations. To test this hypothesis, airway hyperreactivity was measured in guinea pigs exposed to chlorpyrifos, a widely used organophosphate pesticide. Electrical stimulation of the vagus nerves caused frequency-dependent bronchoconstriction that was significantly potentiated in animals 24 h or 7 days after a single subcutaneous injection of either 390 mg/kg or 70 mg/kg of chlorpyrifos, respectively. Mechanisms by which chlorpyrifos may cause airway hyperreactivity include inhibition of acetylcholinesterase (AChE) or dysfunction of M3 muscarinic receptors on airway smooth muscle or of autoinhibitory M2 muscarinic receptors on parasympathetic nerves in the lung. AChE activity in the lung was significantly inhibited 24 h after treatment with 390 mg/kg of chlorpyrifos, but not 7 days after injection of 70 mg/kg of chlorpyrifos. Acute exposure to eserine (250 μ g/ml) also significantly inhibited lung AChE but did not potentiate vagally induced bronchoconstriction. Neuronal M2 receptor function was tested using the M2 agonist pilocarpine, which inhibits vagally induced bronchoconstriction in control animals. In chlorpyrifos-treated animals, pilocarpine dose-response curves were shifted significantly to the right, demonstrating decreased responsiveness of neuronal M2 receptors. In contrast, chlorpyrifos treatment did not alter methacholine-induced bronchoconstriction, suggesting that chlorpyrifos does not alter M3 muscarinic receptor function on airway smooth muscle. These data demonstrate that organophosphate insecticides can cause airway hyperreactivity in the absence of AChE inhibition by decreasing neuronal M2 receptor function.

asthma; pesticide; muscarinic receptor; cholinesterase

OVER THE PAST 20 YEARS there has been a significant increase in the incidence of asthma in industrialized nations, particularly in children in urban settings (33). Over this same period, the use of insecticides, particularly organophosphate insecticides, has increased significantly not only in agricultural (26, 45, 71, 75) but also residential and urban settings (6, 15, 50, 73, 74). A number of clinical and epidemiological studies have linked exposure to organophosphates to airway hyperreactivity and other symptoms of asthma (12, 19, 35, 59). However, the association between organophosphates and asthma has not been tested in an experimental model system and the mechanism(s) by which this class of insecticides causes changes in airway function remains speculative.

Address for reprint requests and other correspondence: D. A. Jett, National Institutes of Health National Institute of Neurological Disorders and Stroke, 6001 Executive Blvd. NSC, Suite 2149, MSC 9535, Bethesda, MD 20892-9835 (E-mail: dj140o@nih.gov).

In the lung, cholinergic nerves in the vagi mediate airway tone and reactivity. These nerves release acetylcholine onto M3 muscarinic receptors causing contraction of airway smooth muscle, resulting in bronchoconstriction. Vagally induced bronchoconstriction is limited by autoinhibitory M2 muscarinic receptors on parasympathetic nerves (28, 54). Previous studies have shown that neuronal M2 receptors are dysfunctional in animal models of asthma (29, 31, 37) and in patients with asthma (55). Loss of M2 receptor function leads to increased release of acetylcholine from the parasympathetic nerves resulting in potentiation of vagally mediated bronchoconstriction, which contributes to airway hyperreactivity.

Organophosphates are known to alter cholinergic function in the brain (53, 60). The generally accepted mechanism of organophosphate neurotoxicity following acute exposure to high doses is inhibition of acetylcholinesterase (AChE). It has been proposed that this same mechanism underlies the effects of organophosphate insecticides on bronchoconstriction (14, 67). However, there is evidence that in the brain, low-level doses of organophosphate pesticides that do not inhibit AChE may alter cholinergic neurotransmission via direct effects on muscarinic and nicotinic receptor function (1, 7, 36, 39, 40, 42–44). These observations led us to test whether chlorpyrifos (Dursban, Lorsban), a commonly used organophosphate with documented widespread human exposure (15, 17, 25, 34, 48), potentiates vagally induced bronchoconstriction by increasing cholinergic drive in the lungs via inhibition of AChE and/or alteration of neuronal M2 or airway smooth muscle M3 muscarinic receptor function.

METHODS

Animals. Specific pathogen-free male guinea pigs (300–350 g) were shipped from Hilltop Lab Animals (Scottsdale, PA) in filtered crates, housed in high-efficiency, particulate-filtered air, and fed a normal diet (Prolab; Agway, Syracuse, NY). All protocols were approved by The Johns Hopkins University Animal Care and Use Committee.

Chlorpyrifos and eserine exposure. Chlorpyrifos (*o,o*-diethyl *o*-[3,5,6-trichloro-2-pyridinol] phosphorothionate, 99.5% pure) was purchased from Chem Service (West Chester, PA) and used within 1 mo of purchase with interim storage as recommended by the manufacturer. Chlorpyrifos dissolved in peanut oil at 70 mg/kg or 390 mg/kg or an equal volume (300 μ l) of peanut oil alone was administered to guinea pigs by subcutaneous injection in the subscapular region. Although the most significant routes of chlorpyrifos exposure in humans are oral ingestion and inhalation (30), subcutaneous dosing is commonly used in mechanistic studies of chlorpyrifos and other organophosphates (13, 16, 62, 70). Subcutaneous administration of

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

chlorpyrifos allows gradual release into the systemic circulation (63), which closely resembles human exposures (30). The guinea pig throat anatomy occludes a stomach tube more so than with rats or mice. Thus the subcutaneous method is also much less stressful to a guinea pig relative to gavage. Animals dosed with chlorpyrifos were monitored for signs of cholinergic intoxication (tremors, altered gait, and excessive excretions) at 1 and 24 h following injections. Guinea pigs given 70 mg/kg sc were tested for airway hyperreactivity 7 days postinjection, whereas animals receiving 390 mg/kg sc were tested 24 h later. These dosing paradigms were found to inhibit lung AChE activity by 0 and 50%, respectively (see Fig. 1), approximating the organophosphate exposures typically observed in humans, which include chronic exposure to low doses that have negligible effect on AChE or acute/subacute exposure to doses that significantly inhibit AChE (30). A 50% inhibition of AChE was chosen as a target value since this level of AChE inhibition is not uncommon in acutely exposed humans (30), and overt toxicity to chlorpyrifos in rodents becomes manifest when brain AChE is inhibited by >60% (57). Vehicle controls treated with peanut oil subcutaneously were tested 7 days later, and since the physiological values obtained with these animals did not differ from those measured in animals that were tested 24 h after saline injections (see Fig. 2), peanut oil controls were not performed for the cohort of animals tested 24 h after chlorpyrifos injection. Eserine was dissolved in sterile saline and administered at a dosage of 0.25 mg/kg iv to anesthetized animals 15 min before physiological measurements, as described below.

Anesthesia and measurement of pulmonary inflation pressure. Guinea pigs were anesthetized (1.5 g/kg urethane ip), and blood pressure and heart rate were measured from the carotid artery. Both jugular veins were cannulated for administration of drugs. Both vagus nerves were cut and placed on electrodes under oil. Succinylcholine (10 μ g/kg iv) was infused to paralyze the animals, and they were ventilated via a tracheal cannula with a positive pressure constant volume (1 ml/100 g body wt and 100 breaths/min). Pulmonary inflation pressure (P_{pi}) was measured via a side arm at the trachea; bronchoconstriction was measured as the increase in P_{pi} over the pressure produced by the ventilator as previously described (28, 29, 37).

Measurement of vagally induced bronchoconstriction. Noradrenaline was depleted 25 min before the start of the experiment with guanethidine (10 mg/kg iv). Both vagi were stimulated (0.2 ms, 10 V,




Fig. 1. Mean acetylcholinesterase (AChE) levels in the lungs of guinea pigs treated with vehicle were 3.8 ± 0.15 μ mol substrate \cdot min $^{-1}\cdot$ mg $^{-1}$ protein. Treatment of animals with a single dose of 70 mg/kg of chlorpyrifos (CPF) did not inhibit AChE activity in the lungs 7 days postinjection (open bar). In contrast, 390 mg/kg of chlorpyrifos after 24 h (gray bar) and 250 μ g/kg of eserine (solid bar) significantly inhibited AChE activity in the lungs. Each point is the mean \pm SE of 5–8 animals presented as a % of control. *Significantly different from control.




Fig. 2. Electrical stimulation of the vagus nerves (1–25 Hz, 10 V, 0.2 ms, 5-s train) produced frequency-dependent bronchoconstriction in the lungs, measured as an increase in pulmonary inflation pressure (P_{pi} ; \square). Vagally induced bronchoconstriction was significantly increased in animals 7 days after a single dose of 70 mg/kg of chlorpyrifos (\blacktriangle) and 24 h after a dose of 390 mg/kg of chlorpyrifos (\blacktriangledown). Frequency response curves in animals 7 days after treatment once with peanut oil vehicle (\circ) or acutely with 250 μ g/kg of eserine (iv; \bullet), a nonorganophosphate AChE inhibitor, were not different from control animals. Each point is the mean \pm SE of 5–8 animals. *Significantly different from control.

1–25 Hz, 5-s duration at 2-min intervals) producing frequency-dependent bronchoconstriction and bradycardia due to release of acetylcholine onto postjunctional M2 muscarinic receptors in the heart and postjunctional M3 muscarinic receptors in the lungs. Both vagally induced bronchoconstriction and bradycardia could be abolished by atropine (1 mg/kg iv).

Measurement of neuronal M2 and smooth muscle M3 muscarinic receptor function. The function of neuronal M2 receptors was determined using a standard assay (28, 29, 37): the ability of the muscarinic agonist pilocarpine to inhibit the bronchoconstrictor response to vagal stimulation at 2 Hz. Pilocarpine inhibits vagally induced bronchoconstriction via stimulation of the neuronal M2 receptors at doses that are 100-fold less than the doses required to cause bronchoconstriction by stimulating postjunctional M3 receptors (28). The effect of pilocarpine on vagally induced bronchoconstriction is reported as the ratio of bronchoconstriction in the presence of pilocarpine to bronchoconstriction in the absence of pilocarpine. Decreased inhibition by pilocarpine of vagally induced bronchoconstriction, manifested as a shift to the right of the dose-response curve, indicates M2 receptor dysfunction (28, 29, 37).

In vagotomized guinea pigs, parasympathetic nerves that release acetylcholine and contain M2 receptor are absent. To assess the effects of organophosphates on M3 muscarinic receptor function in airway smooth muscle and to bypass endogenous acetylcholine release from parasympathetic nerves, we measured bronchoconstriction in vagotomized guinea pigs in response to methacholine (1–10 μ g/kg iv), which is not readily metabolized by AChE (11, 56), and acetylcholine (1–8 μ g/kg iv). The dose-response curve of bronchoconstriction in response to acetylcholine was compared with that of methacholine as well as with vagally induced bronchoconstriction to determine whether changes in vagally induced bronchoconstriction occur via changes in the nerves, in AChE activity, or postjunctional M3 receptor function.

AChE assay. Immediately after the completion of physiological measurements, lungs, brain, and heparinized blood samples were

obtained for determination of AChE activity via the standard Ellman assay (23) using DTNB and acetylthiocholine iodide (ASChI) as the substrate. Assays were run against blanks containing DTNB. The reaction was started with the addition of ASChI after equilibration for 2–3 min. Hydrolysis of ASChI was determined by monitoring the change in absorbance at 405 nm. To inhibit pseudocholinesterase activity, 100 μ M tetraisopropyl pyrophosphoramidate was included in the assay. Data from lung and brain samples were normalized using protein concentration determined using the bicinchoninic assay according to the manufacturer's directions (Pierce, Rockford, IL). AChE activity in blood samples was normalized according to the number of red blood cells as determined using a hemacytometer.

Statistics. Data are expressed as means \pm SE. Frequency, pilocarpine, methacholine, and acetylcholine dose-response curves were analyzed using a two-way analysis of variance for repeated measures. Baseline heart rates (beats/minute), blood pressures (mmHg), P_{pi} (mmH₂O), and changes in P_{pi} (mmH₂O before pilocarpine administration) as well as AChE activity levels (as % of control) were analyzed using ANOVA (Statview 4.5; Abacus Concepts, Berkeley, CA). A *P* value of 0.05 was considered significant.

RESULTS

Treatment with chlorpyrifos did not result in any apparent signs of cholinergic intoxication in guinea pigs 1 or 24 h after subcutaneous injections of 70 or 390 mg/kg. AChE activity in the lungs was not altered 7 days after a single injection of 70 mg/kg of chlorpyrifos (Fig. 1). However, 24 h after a single injection of 390 mg/kg of chlorpyrifos, lung AChE was significantly inhibited by 50%. Acute exposure to 250 μ g/kg of eserine, a nonorganophosphate anticholinesterase, caused a level of AChE inhibition that was not significantly different from that observed with the higher dose of chlorpyrifos (Fig. 1).

Neither chlorpyrifos nor peanut oil altered baseline P_{pi} (control 91 ± 7 mmH₂O, peanut oil 96 ± 5 mmH₂O, 70 mg/kg of chlorpyrifos 87 ± 7 mmH₂O, 390 mg/kg of chlorpyrifos 96 ± 5 mmH₂O), resting heart rate (control 281 ± 11 beats/min, peanut oil 271 ± 8 beats/min, 70 mg/kg of chlorpyrifos 268 ± 9 beats/min, 390 mg/kg of chlorpyrifos 300 ± 7 beats/min), or resting diastolic blood pressure (control 45 ± 2.3 mmHg, peanut oil 41 ± 2 mmHg, 70 mg/kg of chlorpyrifos 46 ± 2 mmHg, 390 mg/kg of chlorpyrifos 56 ± 2.4 mmHg) in vagotomized, anesthetized guinea pigs.

Electrical stimulation of both vagi (1–25 Hz) caused a frequency-dependent increase in bronchoconstriction that was significantly potentiated in animals 24 h after a single injection of 390 mg/kg of chlorpyrifos or 7 days after a single injection of 70 mg/kg of chlorpyrifos (Fig. 2). However, a greater increase in bronchoconstriction was observed in animals that received the acute high-dose chlorpyrifos treatment. In contrast, eserine, which significantly inhibited AChE (Fig. 1), did not potentiate vagally induced bronchoconstriction. Vagally induced bronchoconstriction was not altered in animals receiving vehicle alone (peanut oil) relative to control animals.

Neuronal M2 receptor function was tested in chlorpyrifos-treated animals using the muscarinic agonist pilocarpine. Before pilocarpine was administered, simultaneous electrical stimulation of both vagus nerves (2 Hz, 0.2 ms, 5–20 V, 22 s at 1-min intervals) produced transient bronchoconstriction (measured as an increase in P_{pi}) that did not differ among groups (control 27.6 ± 0.2 mmH₂O, peanut oil 19.8 ± 3 mmH₂O, 70 mg/kg of chlorpyrifos 18.6 ± 5 mmH₂O, 390

mg/kg of chlorpyrifos 24.6 ± 6 mmH₂O). In guinea pigs treated with peanut oil, pilocarpine (1–100 μ g/kg iv) dose dependently inhibited vagally induced bronchoconstriction, demonstrating that the neuronal M2 receptors are functional (Fig. 3, \circ). The effect was identical to saline-treated controls (not shown), demonstrating that injection of peanut oil subcutaneously for 7 days did not alter the function of neuronal M2 receptors. The dose-response curve to pilocarpine was shifted significantly to the right in animals 24 h after treatment with chlorpyrifos at 390 mg/kg. A lesser, but still significant, rightward shift was observed 7 days after treatment with 70 mg/kg of chlorpyrifos. Shifting of the pilocarpine dose-response curve to the right is consistent with decreased function of the M2 receptors.

To test the direct response of M3 receptors on airway smooth muscle to muscarinic agonists, bronchoconstriction induced by intravenous methacholine, which is not rapidly metabolized by AChE, and by intravenous acetylcholine was measured in vagotomized guinea pigs. Chlorpyrifos treatment did not alter methacholine-induced bronchoconstriction (Fig. 4A). Because M2 receptors on vagus nerves were not present in these vagotomized guinea pigs, the absence of an effect on methacholine-induced bronchoconstriction indicates that chlorpyrifos does not affect the ability of agonists to interact with postjunctional M3 muscarinic receptors. Acetylcholine-induced bronchoconstriction was significantly increased in animals treated with 390 mg/kg of chlorpyrifos (Fig. 4B). Eserine at a dosage of 250 μ g/kg also potentiated acetylcholine-induced bronchoconstriction, and although the eserine dose response did not differ significantly from the control dose-response curve, it also did not differ significantly from the dose-response curve obtained from animals treated with 390 mg/kg of chlorpyrifos. Thus eserine potentiated bronchoconstriction to an intermediate level between that of control




Fig. 3. Neuronal M2 receptor function was tested using pilocarpine. Increasing doses of pilocarpine inhibited vagally induced bronchoconstriction in a dose-related manner in animals 7 days after treatment with peanut oil vehicle (\circ), demonstrating the presence of functional M2 receptors. The effect of pilocarpine was shifted significantly to the right in animals 7 days after treatment with 70 mg/kg of chlorpyrifos (\blacktriangle). In the animals treated with 390 mg/kg of chlorpyrifos (\blacktriangledown), pilocarpine did not inhibit vagally induced bronchoconstriction, indicating neuronal M2 muscarinic receptor dysfunction after 24 h. Each point is the mean \pm SE of 5 animals. *Significantly different from control.




Fig. 4. A: methacholine (1–10 $\mu\text{g}/\text{kg}$ iv)-induced bronchoconstriction in vagotomized guinea pigs was not different between peanut oil (○)- or chlorpyrifos-treated guinea pigs (7 days after 70 mg/kg of chlorpyrifos, ▲; and 24 h after 390 mg/kg of chlorpyrifos, ▼). B: acetylcholine (1–10 $\mu\text{g}/\text{kg}$ iv)-induced bronchoconstriction in vagotomized guinea pigs was significantly potentiated by 390 mg/kg of chlorpyrifos, whereas 70 mg/kg of chlorpyrifos had no effect. Acute treatment with 250 $\mu\text{g}/\text{kg}$ of eserine (iv, ●) caused a small but not statistically significant potentiation of acetylcholine-induced bronchoconstriction. Each point is the mean \pm SE of 5 animals. *Significantly different from control; d, days.

animals and animals treated with 390 mg/kg of chlorpyrifos. Treatment of animals with 70 mg/kg of chlorpyrifos for 7 days had no effect on acetylcholine-induced bronchoconstriction. The potentiation of acetylcholine-induced bronchoconstriction by the higher dose of chlorpyrifos and by eserine is consistent with the inhibition of AChE by these treatments (see Fig. 1).

M2 muscarinic receptors are also present in the heart. Thus we measured vagally induced bradycardia to determine whether organophosphate insecticides alter M2 muscarinic receptors in tissues other than the lung. In the heart, stimulation of the vagus nerves (1–25 Hz) produces bradycardia that is frequency dependent (Fig. 5). Treatment with 70 mg/kg of chlorpyrifos did not alter the vagally induced fall in heart rate relative to control. However, in the animals treated with 390 mg/kg of chlorpyrifos for 24 h, the frequency response curve was potentiated at frequencies <20 Hz (Fig. 5). At 20 and 25 Hz, the fall in heart rate approaches maximum, and the differences are no longer significant. However, the potentiation of vagally induced bradycardia by the higher dose of chlorpyrifos does not appear to be mediated by inhibition of AChE since eserine at a concentration that significantly inhibits AChE does not potentiate vagally induced bradycardia (Fig. 5). Methacholine- and acetylcholine-induced bradycardia was not altered by either high- or low-dose chlorpyrifos treatment (Fig. 6) despite inhibition of AChE by the higher dose of chlorpyrifos.

DISCUSSION

In humans, exposure to organophosphate insecticides and other pesticides has been associated with a variety of respiratory symptoms, including decreased forced expiratory volume in 1 min, wheeze, cough, and shortness of breath (3, 19, 35, 46, 47, 65, 67). Similarly, it has been reported that organophos-




Fig. 5. Electrical stimulation of the vagus nerves (1–25 Hz, 10 V, 0.2 ms, 5-s train) produced frequency-dependent bradycardia in the heart measured as a fall in heart rate (○). Vagally induced bradycardia in animals 7 days after treatment with 70 mg/kg of chlorpyrifos (▲) or acutely with 250 $\mu\text{g}/\text{kg}$ of eserine (●) was not significantly different from peanut oil-treated animals. However, vagally induced bradycardia in animals treated with 390 mg/kg of chlorpyrifos after 24 h (▼) was shifted to the left. Up until 20 Hz, the shift was significantly different from oil control; however, at 20 and 25 Hz, the fall in heart rate was approaching maximum, and the differences were no longer significant. Each point is the mean \pm SE of 5–8 animals.

phate insecticides induce bronchospasm in a variety of animals (20, 32, 66). Our data provide more direct evidence of a causal link between organophosphate exposure and airway hyperreactivity. Specifically, we observed that vagally induced bronchoconstriction in guinea pig lungs is significantly potentiated




Fig. 6. A: methacholine (1–10 $\mu\text{g}/\text{kg}$ iv)-induced bradycardia in vagotomized guinea pigs was not different between peanut oil (○)- or chlorpyrifos-treated guinea pigs (7 days after 70 mg/kg of chlorpyrifos, ▲; and 24 h after 390 mg/kg of chlorpyrifos, ▼). B: acetylcholine (1–10 $\mu\text{g}/\text{kg}$ iv)-induced bradycardia in vagotomized guinea pigs was not different between peanut oil (○)- or chlorpyrifos-treated guinea pigs (7 days after 70 mg/kg of chlorpyrifos, ▲; and 24 h after 390 mg/kg of chlorpyrifos, ▼). Each point is the mean \pm SE of 5 animals.

following either acute (24 h after 390 mg/kg of chlorpyrifos) or chronic (7 days after 70 mg/kg) exposure to chlorpyrifos.

It has been proposed that if organophosphates contribute to asthma, it is likely due to inhibition of AChE (14, 24, 67), which is the principal mechanism underlying acute organophosphate neurotoxicity. Support for this hypothesis includes observations that not only organophosphate insecticides, but also other structurally unrelated AChE-inhibiting insecticides, such as carbaryl, enhance airway hyperreactivity in rats (20) and humans (67). However, two observations from our studies suggest mechanisms other than AChE inhibition mediate chlorpyrifos effects on vagally induced bronchoconstriction. First, our data indicate that animals tested 7 days after receiving 70 mg/kg of chlorpyrifos (subcutaneously) exhibit airway hyperreactivity in the absence of AChE inhibition. Second, acute administration of the nonorganophosphate eserine at a dose (250 μ g/ml) that significantly inhibits AChE does not potentiate vagally induced bronchoconstriction. Similarly, a poor correlation has been noted between cholinesterase inhibition and toxic effects in the brain by some organophosphate insecticides (22), prompting investigations of alternative mechanisms of neurotoxicity. These observations are important because they suggest that toxicity from some organophosphates may occur below thresholds of exposure normally defined by AChE inhibition.

Neuronal M2 muscarinic receptors limit release of acetylcholine from the vagus nerves in the lungs (28). Pharmacological blockade of neuronal M2 receptors increases release of acetylcholine from the nerves (5, 27), which potentiates vagally induced bronchoconstriction (28, 29, 37). Our data show that neuronal M2 receptor function is inhibited by both high and low doses of chlorpyrifos, consistent with other findings that organophosphate insecticides act on muscarinic receptors in the brain (1, 36, 38, 43). This effect of chlorpyrifos on vagally induced bronchoconstriction is dependent on the dosing regimen. Vagally induced bronchoconstriction was significantly greater in animals treated with the high dose of chlorpyrifos relative to animals treated with the low dose (Fig. 2). A similar dependency was observed for the effects of chlorpyrifos on M2 receptor function as determined by pilocarpine dose-response curves (Fig. 3). In contrast, neither dose of chlorpyrifos changed the response to intravenous methacholine, demonstrating that the function of M3 muscarinic receptors on airway smooth muscle was not altered in animals in which M2 receptors mediating ACh release were not present. Selective loss of neuronal M2 receptor function in the lungs is also associated with other models of airway hyperreactivity, including antigen challenge (29), viral infection (37), and exposure to ozone (31), suggesting that decreased M2 receptor function on airway nerves is a generalized mechanism underlying airway hyperreactivity.

The ability of organophosphate insecticides to inhibit neuronal M2 receptors may not be restricted to the lungs. Organophosphate insecticides have been shown to inhibit muscarinic receptor binding in the brain (1, 7, 36, 39, 40, 43, 44) and bind to a subpopulation of M2 receptors in the heart (68). In the heart, M2 receptors are present on parasympathetic nerves that supply the heart where they function to inhibit release of acetylcholine (52, 58) as well as on cardiac muscle where they mediate bradycardia (10, 51). The single high dose of chlorpyrifos potentiated vagally induced bradycardia but not brady-

cardia induced by intravenous administration of acetylcholine. This is consistent with loss of neuronal M2 receptor function on parasympathetic nerves in the heart resulting in increased release of acetylcholine, which potentiates vagally induced bradycardia. Neither dose of chlorpyrifos altered bradycardia induced by acetylcholine or methacholine administered intravenously, indicating that the postjunctional M2 receptors are not sensitive to organophosphate insecticides, and this is consistent with the sensitivity of neuronal M2 receptors we observed in the lung. These data are also consistent with previous observations that the function of the neuronal M2 receptors in the heart are inhibited by systemic administration of double-stranded RNA, which does not alter the function of postjunctional M2 receptors (9). Thus the neuronal receptors appear to be more vulnerable to inhibition than the postjunctional receptors.

The mechanism(s) by which organophosphate insecticides alter M2 receptor function in the lungs have yet to be elucidated. Mechanisms by which these compounds alter muscarinic receptor function in neurons include downregulation of muscarinic receptor expression (39, 40), modulation of ligand binding to muscarinic receptors (38, 43, 44), and alteration of signal transduction pathways downstream of muscarinic receptor activation (8, 36, 72). *In vitro* studies of cardiac M2 muscarinic receptors have demonstrated that acute exposure to the oxon metabolite of chlorpyrifos alters ligand binding via diethylphosphorylation of the receptor itself (7). Whether these mechanisms underlie the effects of organophosphates on neuronal M2 receptor function in the lung has yet to be determined.

Data presented here indicate that organophosphate insecticides potentiate vagally induced bronchoconstriction via disruption of the cholinergic control of airway responsiveness. A significant finding from our studies is that chlorpyrifos altered neuronal M2 receptor function in the lung at concentrations that did not inhibit AChE. Although the threshold concentration for this effect was not determined in our studies, it has been shown that ligand binding to muscarinic receptors in the brain (43) as well as signaling pathways downstream of muscarinic receptor binding (64) can be disrupted by very low (nanomolar to picomolar) concentrations of organophosphate insecticides. These data suggest that exposure to not only occupational, but also environmental, levels of these compounds may have biological consequences. The significance of these findings to public health is heightened by evidence of widespread human exposure to chlorpyrifos and other organophosphate insecticides (34, 45).

Children represent a potentially sensitive subpopulation with respect to asthma. Thus it is of great concern that in a sample of 84,000 children across the United States, the urinary levels of chlorpyrifos metabolites were above the detection limit 98% of the time, compared with a 4% detection rate for the herbicide atrazine (2). Many of the organophosphate insecticides have been restricted or banned due to their developmental neurotoxicity in animals. However, many of these compounds, including chlorpyrifos, are still used commercially in both agricultural settings and urban environments. These pesticide usage patterns correlate positively with reports of high incidence of asthma morbidity in agricultural workers (3, 35, 41, 46, 67, 69, 76) and in residents of the inner cities of the United States (18, 33, 49, 61). The coincident rise in the incidence of

asthma (33) and in the use of organophosphate insecticides (26, 45, 71, 75) suggests a potential causal relationship between these two observations, which is corroborated by our data obtained using an animal model of airway hyperreactivity. Our data raise significant questions regarding the current use of organophosphate insecticides in the inner cities to control cockroach antigen (6, 15, 50, 73, 74), which itself has been associated with asthma (4, 21), and suggest that exposure to insecticides may be contributing to rather than ameliorating asthma.

ACKNOWLEDGMENTS

We thank Emily Ray for technical assistance.

GRANTS

This work was supported by United States Department of Defense Grant DAMD17-02-1-0188 (to A. D. Fryer) and National Institute of Environmental Health Sciences Grants T32-ES-07141 (to A. S. Howard) and 1-R21-ES-11771 (to P. J. Lein).

REFERENCES

1. Abdallah EA, Jett DA, Eldefrawi ME, and Eldefrawi AT. Differential effects of paraoxon on the M3 muscarinic receptor and its effector system in rat submaxillary gland cells. *J Biochem Toxicol* 7: 125–132, 1992.
2. Adgate JL, Barr DB, Clayton CA, Eberly LE, Freeman NC, Lioy PJ, Needham LL, Pellizzari ED, Quackenboss JJ, Roy A, and Sexton K. Measurement of children's exposure to pesticides: analysis of urinary metabolite levels in a probability-based sample. *Environ Health Perspect* 109: 583–590, 2001.
3. Arif AA, Whitehead LW, Delclos GL, Tortolero SR, and Lee ES. Prevalence and risk factors of work related asthma by industry among United States workers: data from the third national health and nutrition examination survey (1988–1994). *Occup Environ Med* 59: 505–511, 2002.
4. Arruda LK, Vailes LD, Ferriani VP, Santos AB, Pomes A, and Chapman MD. Cockroach allergens and asthma. *J Allergy Clin Immunol* 107: 419–428, 2001.
5. Baker DG, Don HF, and Brown JK. Direct measurement of acetylcholine release in guinea pig trachea. *Am J Physiol Lung Cell Mol Physiol* 263: L142–L147, 1992.
6. Berkowitz GS, Obel J, Deych E, Lapinski R, Godbold J, Liu Z, Landrigan PJ, and Wolff MS. Exposure to indoor pesticides during pregnancy in a multiethnic, urban cohort. *Environ Health Perspect* 111: 79–84, 2003.
7. Bomser JA and Casida JE. Diethylphosphorylation of rat cardiac M2 muscarinic receptor by chlorpyrifos oxon in vitro. *Toxicol Lett* 119: 21–26, 2001.
8. Bomser JA, Quistad GB, and Casida JE. Chlorpyrifos oxon potentiates diacylglycerol-induced extracellular signal-regulated kinase (ERK 44/42) activation, possibly by diacylglycerol lipase inhibition. *Toxicol Appl Pharmacol* 178: 29–36, 2002.
9. Bowerfind WM, Fryer AD, and Jacoby DB. Double-stranded RNA causes airway hyperreactivity and neuronal M2 muscarinic receptor dysfunction. *J Appl Physiol* 92: 1417–1422, 2002.
10. Brodde OE, Bruck H, Leineweber K, and Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. *Basic Res Cardiol* 96: 528–538, 2001.
11. Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pffaffendorf M, and van Zwieten PA. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. *Blood Press* 5: 333–341, 1996.
12. Bryant DH. Asthma due to insecticide sensitivity. *Aust NZ J Med* 15: 66–68, 1985.
13. Bushnell PJ, Padilla SS, Ward T, Pope CN, and Olszyk VB. Behavioral and neurochemical changes in rats dosed repeatedly with diisopropylfluorophosphate. *J Pharmacol Exp Ther* 256: 741–750, 1991.
14. Casarett LJ and Doull J. *Toxicology*. New York: Macmillan, 1975.
15. CDC. *Second National Report on Human Exposure to Environmental Chemicals*. Atlanta, GA: National Center for Environmental Health, 2003.
16. Chiappa S, Padilla S, Koenigsberger C, Moser V, and Brimijoin S. Slow accumulation of acetylcholinesterase in rat brain during enzyme inhibition by repeated dosing with chlorpyrifos. *Biochem Pharmacol* 49: 955–963, 1995.
17. Davis DL and Ahmed AK. Exposures from indoor spraying of chlorpyrifos pose greater health risks to children than currently estimated. *Environ Health Perspect* 106: 299–301, 1998.
18. Delfino RJ, Gong H Jr, Linn WS, Pellizzari ED, and Hu Y. Asthma symptoms in Hispanic children and daily ambient exposures to toxic and criteria air pollutants. *Environ Health Perspect* 111: 647–656, 2003.
19. Deschamps D, Questel F, Baud FJ, Gervais P, and Dally S. Persistent asthma after acute inhalation of organophosphate insecticide. *Lancet* 344: 1712, 1994.
20. Dong W, Gilmour MI, Lambert AL, and Selgrade MK. Enhanced allergic responses to house dust mite by oral exposure to carbaryl in rats. *Toxicol Sci* 44: 63–69, 1998.
21. Eggleston PA and Arruda LK. Ecology and elimination of cockroaches and allergens in the home. *J Allergy Clin Immunol* 107: S422–S429, 2001.
22. Eldefrawi AT, Jett DA, and Eldefrawi ME. Direct actions of organophosphate anticholinesterases on muscarinic receptors. In: *Organophosphates: Chemistry, Fate and Effects*, edited by Chambers JE and Levi PE. New York: Academic, 1992, p. 419–432.
23. Ellman GL, Courtney KD, Andres V, and Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 7: 88–95, 1961.
24. Ernst P. Pesticide exposure and asthma. *Am J Respir Crit Care Med* 165: 563–564, 2002.
25. Eskenazi B, Bradman A, and Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. *Environ Health Perspect* 107, Suppl 3: 409–419, 1999.
26. Fenske RA, Lu C, Barr D, and Needham L. Children's exposure to chlorpyrifos and parathion in an agricultural community in central Washington State. *Environ Health Perspect* 110: 549–553, 2002.
27. Fryer AD, Elbon CL, Kim AL, Xiao HQ, Levey AI, and Jacoby DB. Cultures of airway parasympathetic nerves express functional M2 muscarinic receptors. *Am J Respir Cell Mol Biol* 15: 716–725, 1996.
28. Fryer AD and Maclagan J. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. *Br J Pharmacol* 83: 973–978, 1984.
29. Fryer AD and Wills-Karp M. Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. *J Appl Physiol* 71: 2255–2261, 1991.
30. Gallo MA and Lawryk NJ. Organic phosphorus pesticides. In: *Handbook of Pesticide Toxicology*, edited by Hayes WJ and Laws ER. New York: Academic, 1991, p. 917–972.
31. Gambone LM, Elbon CL, and Fryer AD. Ozone-induced loss of neuronal M2 muscarinic receptor function is prevented by cyclophosphamide. *J Appl Physiol* 77: 1492–1499, 1994.
32. Gustin P, Dhem AR, Lomba F, Lekeux P, Van de Woestijne KP, and Landser FJ. Measurement of total respiratory impedance in calves by the forced oscillation technique. *J Appl Physiol* 64: 1786–1791, 1988.
33. Hartert TV and Peebles RS Jr. Epidemiology of asthma: the year in review. *Curr Opin Pulm Med* 6: 4–9, 2000.
34. Hill RH Jr, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL, Williams CC, Sampson EJ, and Needham LL. Pesticide residues in urine of adults living in the United States: reference range concentrations. *Environ Res* 71: 99–108, 1995.
35. Hoppin JA, Umbach DM, London SJ, Alavanja MC, and Sandler DP. Chemical predictors of wheeze among farmer pesticide applicators in the Agricultural Health Study. *Am J Respir Crit Care Med* 165: 683–689, 2002.
36. Huff RA, Corcoran JJ, Anderson JK, and Abou-Donia MB. Chlorpyrifos oxon binds directly to muscarinic receptors and inhibits cAMP accumulation in rat striatum. *J Pharmacol Exp Ther* 269: 329–335, 1994.
37. Jacoby DB and Fryer AD. Virus-induced airway hyperresponsiveness—possible involvement of neural mechanisms. *Am Rev Respir Dis* 144: 1422–1423, 1991.
38. Jett DA, Abdallah EA, El-Fakahany EE, Eldefrawi ME, and Eldefrawi AT. The high affinity activation by paroxon of a muscarinic receptor subtype in rat brain striatum. *Pest Biochem Physiol* 39: 149–157, 1991.
39. Jett DA, Fernando JC, Eldefrawi ME, and Eldefrawi AT. Differential regulation of muscarinic receptor subtypes in rat brain regions by repeated injections of parathion. *Toxicol Lett* 73: 33–41, 1994.

40. Jett DA, Hill EF, Fernando JC, Eldefrawi ME, and Eldefrawi AT. Down-regulation of muscarinic receptors and the m3 subtype in white-footed mice by dietary exposure to parathion. *J Toxicol Environ Health* 39: 395–415, 1993.
41. Jones SM, Burks AW, Spencer HJ, Lensing S, Roberson PK, Gandy J, and Helm RM. Occupational asthma symptoms and respiratory function among aerial pesticide applicators. *Am J Ind Med* 43: 407–417, 2003.
42. Katz EJ, Cortes VI, Eldefrawi ME, and Eldefrawi AT. Chlorpyrifos, parathion, and their oxons bind to and desensitize a nicotinic acetylcholine receptor: relevance to their toxicities. *Toxicol Appl Pharmacol* 146: 227–236, 1997.
43. Katz LS and Marquis JK. Modulation of central muscarinic receptor binding in vitro by ultralow levels of the organophosphate paraoxon. *Toxicol Appl Pharmacol* 101: 114–123, 1989.
44. Katz LS and Marquis JK. Organophosphate-induced alterations in muscarinic receptor binding and phosphoinositide hydrolysis in the human SK-N-SH cell line. *Neurotoxicology* 13: 365–378, 1992.
45. Koch D, Lu C, Fisker-Andersen J, Jolley L, and Fenske RA. Temporal association of children's pesticide exposure and agricultural spraying: report of a longitudinal biological monitoring study. *Environ Health Perspect* 110: 829–833, 2002.
46. Kogevinas M, Anto JM, Sunyer J, Tobias A, Kromhout H, and Burney P. Occupational asthma in Europe and other industrialised areas: a population-based study. European Community Respiratory Health Survey Study Group. *Lancet* 353: 1750–1754, 1999.
47. Konieczny B, Kossman S, and Makuch M. Impaired respiratory muscle function in chemical plant workers producing chlorfenvinphos. *Ann Agric Environ Med* 6: 21–25, 1999.
48. Landrigan PJ, Claudio L, Markowitz SB, Berkowitz GS, Brenner BL, Romero H, Wetmur JG, Matte TD, Gore AC, Godbold JH, and Wolff MS. Pesticides and inner-city children: exposures, risks, and prevention. *Environ Health Perspect* 107, Suppl 3: 431–437, 1999.
49. Landrigan PJ, Schechter CB, Lipton JM, Fahs MC, and Schwartz J. Environmental pollutants and disease in American children: estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities. *Environ Health Perspect* 110: 721–728, 2002.
50. Lu C, Knutson DE, Fisker-Andersen J, and Fenske RA. Biological monitoring survey of organophosphorus pesticide exposure among pre-school children in the Seattle metropolitan area. *Environ Health Perspect* 109: 299–303, 2001.
51. Maeda A, Kubo T, Mishina M, and Numa S. Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. *FEBS Lett* 239: 339–342, 1988.
52. Manabe N, Foldes FF, Torocsik A, Nagashima H, Goldiner PL, and Vizi ES. Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. *J Auton Nerv Syst* 32: 233–242, 1991.
53. Mileson BE, Chambers JE, Chen WL, Dettbarn W, Ehrlich M, Eldefrawi AT, Gaylor DW, Hamernik K, Hodgson E, Karczmar AG, Padilla S, Pope CN, Richardson RJ, Saunders DR, Sheets LP, Sultatos LG, and Wallace KB. Common mechanism of toxicity: a case study of organophosphorus pesticides. *Toxicol Sci* 41: 8–20, 1998.
54. Minette PA and Barnes PJ. Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways. *J Appl Physiol* 64: 2532–2537, 1988.
55. Minette PA, Lammers JW, Dixon CM, McCusker MT, and Barnes PJ. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. *J Appl Physiol* 67: 2461–2465, 1989.
56. Norel X, Angrisani M, Labat C, Gorenne I, Dulmet E, Rossi F, and Brink C. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. *Br J Pharmacol* 108: 914–919, 1993.
57. Nostrandt AC, Padilla S, and Moser VC. The relationship of oral chlorpyrifos effects on behavior, cholinesterase inhibition, and muscarinic receptor density in rat. *Pharmacol Biochem Behav* 58: 15–23, 1997.
58. Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F, and Rump LC. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. *Circulation* 103: 1638–1643, 2001.
59. O'Malley M. Clinical evaluation of pesticide exposure and poisonings. *Lancet* 349: 1161–1166, 1997.
60. Overstreet DH. Organophosphate pesticides, cholinergic function and cognitive performance in advanced age. *Neurotoxicology* 21: 75–81, 2000.
61. Perera FP, Illman SM, Kinney PL, Whyatt RM, Kelvin EA, Shepard P, Evans D, Fullilove M, Ford J, Miller RL, Meyer IH, and Rauh VA. The challenge of preventing environmentally related disease in young children: community-based research in New York City. *Environ Health Perspect* 110: 197–204, 2002.
62. Pope CN, Chakraborti TK, Chapman ML, and Farrar JD. Long-term neurochemical and behavioral effects induced by acute chlorpyrifos treatment. *Pharmacol Biochem Behav* 42: 251–256, 1992.
63. Pope CN, Chakraborti TK, Chapman ML, Farrar JD, and Arthun D. Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides. *Toxicology* 68: 51–61, 1991.
64. Schuh RA, Lein PJ, Beckles RA, and Jett DA. Noncholinesterase mechanisms of chlorpyrifos neurotoxicity: altered phosphorylation of Ca²⁺/cAMP response element binding protein in cultured neurons. *Toxicol Appl Pharmacol* 182: 176–185, 2002.
65. Schwartz DA. Etiology and pathogenesis of airway disease in children and adults from rural communities. *Environ Health Perspect* 107, Suppl 3: 393–401, 1999.
66. Segura P, Chavez J, Montano LM, Vargas MH, Delaunois A, Carbaljal V, and Gustin P. Identification of mechanisms involved in the acute airway toxicity induced by parathion. *Naunyn Schmiedebergs Arch Pharmacol* 360: 699–710, 1999.
67. Senthilvelan A, McDuffie HH, and Dosman JA. Association of asthma with use of pesticides. Results of a cross-sectional survey of farmers. *Am Rev Respir Dis* 146: 884–887, 1992.
68. Silveira CL, Eldefrawi AT, and Eldefrawi ME. Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases. *Toxicol Appl Pharmacol* 103: 474–481, 1990.
69. Sirajuddin H, Roslinah A, Rampal KG, Kuppasamy I, Rohna R, Aziz M, Aw TC, and Beach JR. Notification of occupational and work-related diseases and poisonings in Malaysia, 1997–1998. *Med J Malaysia* 56: 25–31, 2001.
70. Stanton ME, Mundy WR, Ward T, Dulchinos V, and Barry CC. Time-dependent effects of acute chlorpyrifos administration on spatial delayed alternation and cholinergic neurochemistry in weanling rats. *Neurotoxicology* 15: 201–208, 1994.
71. USDA. Agricultural chemicals and production technology. Washington, DC: Economic Research Service, 2003.
72. Ward TR and Mundy WR. Organophosphorus compounds preferentially affect second messenger systems coupled to M2/M4 receptors in rat frontal cortex. *Brain Res Bull* 39: 49–55, 1996.
73. Weisenburger DD. Human health effects of agrichemical use. *Hum Pathol* 24: 571–576, 1993.
74. Whyatt RM, Camann DE, Kinney PL, Reyes A, Ramirez J, Dietrich J, Diaz D, Holmes D, and Perera FP. Residential pesticide use during pregnancy among a cohort of urban minority women. *Environ Health Perspect* 110: 507–514, 2002.
75. Wilhoit L, Davidson N, Supkoff D, Stegall J, Braun A, Simmons S, Hobza B, Hunter C, Gorder N, Goodman C, and Todd B. Pesticide Use Analysis and Trends from 1991 to 1996. Sacramento, CA: State of California Environmental Protection Agency, 1999.
76. Zhang LX, Enarson DA, He GX, Li B, and Chan-Yeung M. Occupational and environmental risk factors for respiratory symptoms in rural Beijing, China. *Eur Respir J* 20: 1525–1531, 2002.